FDA's Warning On Postmarketing Adverse Event Reporting To Actelion Signals Enforcement Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
While still much less frequent than GMP warning letters, PADE letters are on the rise, with FDA focusing on reports for drugs with known serious safety issues.